Glaxosmithkline

Glaxosmithkline's reported carbon emissions

GlaxoSmithKline (GSK), headquartered in GB and operating within the Pharmaceutical Preparation Manufacturing industry, has demonstrated a commitment to reducing its environmental impact. In 2024, the company reported total emissions of approximately 9.4 billion kg CO2e, comprising Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were around 521 million kg CO2e, while Scope 2 emissions (market-based) totalled approximately 44 million kg CO2e. Scope 3 emissions, encompassing the value chain, were approximately 8.39 billion kg CO2e, with significant contributions from purchased goods and services (around 2.8 billion kg CO2e) and the use of sold products (approximately 4.6 billion kg CO2e). GSK has established ambitious climate targets, including achieving net-zero greenhouse gas emissions across its full value chain by 2045. This long-term goal involves an absolute reduction of at least 90% in emissions from a 2020 baseline, with residual emissions being neutralised. For the near term, GSK aims for an 80% reduction in Scope 1 and 2 emissions by 2030, also from a 2020 baseline, with the remaining 20% addressed through investment in nature-based solutions. Correspondingly, Scope 3 emissions are targeted for an 80% reduction by 2030. The company is a signatory to the Climate Pledge, committing to reach net-zero carbon emissions by 2040. In 2021, GSK achieved a 15% reduction in its Scope 1 and 2 carbon emissions compared to 2020. This progress aligns with their near-term targets, demonstrating an ongoing effort to decarbonise their operations and value chain.